8th International Electronic Conference on Synthetic Organic Chemistry. ECSOC-8. 1-30 November 2004. http://www.lugo.usc.es/~qoseijas/ECSOC-8/
Julio A. Seijas,a* M. Pilar Vázquez-Tato,a* Javier Seijo-Muras,a Pablo Ramil-Rego,b M. Inmaculada Bujánb
aDepartamento de Química Orgánica. Universidad de Santiago de Compostela. Facultad de Ciencias. Campus de Lugo. Aptdo. 280. 27080-Lugo. Spain
Narcissus bulbocodium L. is an amaryllidaceae plant growing in the wild of Western France, Spain, Portugal and Morocco and is by far the most common and widespread of the hoop-petticoat daffodils. To our knowledge no phytochemical studies were carried out for this plant, despite that its habitat covers a wide area . In this communication we present the preliminary results of the study of specimens collected in Lugo-Galicia (NW Spain).
Figure 1
The basic fraction from the methanolic extract was purified affording several alkaloids. The major components which were fully characterized are: galanthamine (1), sanguinine (2), haemanthamine (3), tazetine (4), pretazetine (5) and ismine (6).
Galanthamine, one of the major alkaloids in this plant, is a specific, competitive, and reversible acetylcholinesterase inhibitor. It is also an allosteric modulator at nicotinic cholinergic receptor sites potentiating cholinergic nicotinic neurotransmission, and a small number of early studies showed mild cognitive and global benefits for patients with Alzheimer's disease.[1] Sanguinine shows a skeleton similar to that of galanthamine, it is also an acetylcholinesterase inhibitor, being more potent than 1[2]. Haemanthamine shows antimalarial activity[3], displaying also pronounced cell growth inhibitory activities against both drug-sensitive and drug-resistant cell lines[4], together with high antiretroviral activities[5]. Previous to our work, ismine had been only isolated from Narcissus species (N. asturiensis)[6], and shows hypotensive activity[7].
Our current investigation aims to the isolation and identification of minor components in Narcissus bulbocodium.
XUNTA DE GALICIA for financial support: PGIDT01PXI26203PR and PR405 A 098/59-0.
REFERENCES
1.- Sramek, J.J.; Frackiewicz, E.J.; Cutler, N.R. Expert Opin Investig Drugs.
2000, 2393-2402.
2.- López, S.; Bastida,J.; Viladomat, F.; Codina, C.
Life Sciences 2002, 71, 2521–2529
3.- Bilge ener
1, Ilkay Orhan 1 *, Jutamad
Satayavivad 2Phytotherapy Research 2003Volume
17, Issue 10 , Pages 1220 - 1223
4.- Judit Hohmann1, Peter Forgo2, Joseph Molnár3, Krisztina Wolfard3, Annamária Molnár3, Theresia Thalhammer4, Imre Máthé1, Derek Sharples5Planta med 2002; 68: 454-457
5.- László Szlávik, Ágnes Gyuris1, János Minárovits1, Peter Forgo2, József Molnár3, Judit Hohmann Planta med 2004; 70: 871-873
6.- Viladomat, F.; Selles, M.; Codina, C.; Bastida, J. Departamento Productes Naturals, Facultat Farmacia, Universitat Barcelona, Barcelona, Spain. Planta Medica (1997), 63(6), 583.
7.-Schmeda-Hirschmann, G.; Rodríguez, J. A.; Loyola, J. I.; Astudillo, L.;
Bastida, J.; Viladomat, F.; Codina, C. Pharm. Pharmacol. Commun.
2000, 6, 309-312.